Reishilab Sdn Bhd

9 records, newest first. Each line links to the FDA page it came from.

Refusal charges, in plain English

• HEALTH C8 refused lines

  Unauthorized nutrient content or health claim

  The label or labeling appeared to carry a nutrient content claim or health claim that is not authorized.

• NCONTACT8 refused lines

  No U.S. adverse event contact on supplement label

  The dietary supplement label appeared not to show a U.S. address or phone number through which a serious adverse event can be reported.

• NUTRIT LBL8 refused lines

  Nutrition information missing from label

  The label or labeling appeared not to carry the nutrition information that U.S. law requires for the food.

• UNAPPROVED8 refused lines

  Unapproved new drug

  The product appeared to be a new drug within the meaning of section 201(p) of the FD&C Act without an approved New Drug Application. FDA can apply this charge to a food or supplement whose labeling presents it for drug uses.

Questions about Reishilab Sdn Bhd

Is Reishilab Sdn Bhd on an FDA import alert?

Yes. As of October 26, 2026, Reishilab Sdn Bhd is on the red list of FDA Import Alert 99-39, “Imported foods that appear to be misbranded”, for ashiguard capsules; FDA published the listing on May 20, 2019.

Has FDA refused shipments from Reishilab Sdn Bhd?

Yes. FDA refused 8 shipment lines from Reishilab Sdn Bhd between March 26, 2019 and April 23, 2019. The most recent, on April 23, 2019, was vitamin, mineral, proteins and unconventional dietary specialities for humans and animals, n.e.c., charged as NCONTACT (no u.s. adverse event contact on supplement label).

Why did FDA refuse Reishilab Sdn Bhd's shipments?

The most frequent charges are HEALTH C (unauthorized nutrient content or health claim, 8 lines) and NCONTACT (no u.s. adverse event contact on supplement label, 8 lines).

What is Reishilab Sdn Bhd's FEI number?

Reishilab Sdn Bhd's FDA Establishment Identifier (FEI) is 3012718658.

Can shipments from Reishilab Sdn Bhd still enter the U.S.?

Shipments of ashiguard capsules from Reishilab Sdn Bhd can be detained without physical examination under Import Alert 99-39; FDA releases them only if evidence shows they do not have the listed violation. Importers must consider this listing in their FSVP evaluation (21 CFR 1.505).